Publications

Search our bibliography using the filters on the right-hand side.

Displaying 251 through 300 of 341 publications.

Maurer M, Weller K, Nakonechna A, Abouzakouk M, Hollis KA, McBride DW, Georgiou P, Balp MM, Grattan C. The first international study assessing the economic and humanistic burden of refractory chronic spontaneous/idiopathic urticaria: aSSURE-CSU. Poster presented at the European Academy of Allergy and Clinical Immunology Congress 2014; June 2014. Copenhagen, Denmark.

Stull D, McBride D, Houghton K, Finlay A, Gnanasakthy A, Balp MM. Changes in urticaria symptoms, dermatologic-related quality of life, and urticaria-specific quality of life: are they telling us the same thing about response to treatment for chronic spontaneous/idiopathic urticaria (CSU/CIU)? Poster presented at the European Academy of Allergy and Clinical Immunology Congress; June 2014. Copenhagen, Denmark.

Lebwohl M, Karpov A, Zhao Y, Mordin MM, Elewski B. Secukinumab impact on patient-reported psoriasis symptoms: an analysis of the psoriasis symptom diary (ERASURE study). Poster presented at the Society of Dermatology Physicians Assistants Annual Summer Dermatology Conference; May 29, 2014. Indianapolis, IN.

Gottlieb AB, Zhao Y, Odom DM, Tran MH, Strober B. Secukinumab's time to psoriasis response on patient-reported psoriasis symptoms (ERASURE study). Poster presented at the Society of Dermatology Physicians Assistants Annual Summer Dermatology Conference; May 29, 2014. Indianapolis, IN. Previously presented at the 72nd Annual Meeting of the American Academy of Dermatology.

Elewski B, McLeod LD, Zhao Y, Mallya U, Lewbhol M. Placebo or etanercept on time to response on patient-reported psoriasis symptoms of pain, itching, and scaling (FIXTURE Study). Poster presented at the 72nd Annual Meeting of the American Academy of Dermatology; March 21, 2014.

Elewski B, McLeod LD, Zhao Y, Mallya U, Lewbhol M. Secukinumab versus placebo or etanercept on time to response on patient-reported psoriasis symptoms of pain, itching, and scaling (fixture study). Poster presented at the 72nd Annual Meeting of the American Academy of Dermatology; March 21, 2014. Denver, CO.

Gottlieb A, Zhang J, Gnanasakthy A, Tran MH, Strober B. Secukinumab's time to psoriasis response on patient-reported psoriasis symptoms (ERASURE Study). Poster presented at the 72nd Annual Meeting of the American Academy of Dermatology; March 21, 2014. Denver, CO.

Stull D, McBride D, Houghton K, Finlay A, Balp MM. Correlation between changes in weekly disease severity score and quality of life scores in chronic spontaneous/idiopathic urticaria (CSU/CIU): are they equally informative about the response to treatment? Poster presented at the AAAAI Annual Meeting; February 28, 2014. San Diego, CA.

Stull DE, McBride D, Gnanasakthy A, Balp M. Correlations between changes in the urticaria activity score (UAS7) and the dermatology life quality index (DLQI) from baseline to 28 or 40 weeks: comparisons of trajectories of change in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU). Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A509.

Chisaguano AM, Montes R, Perez-Berezo T, Castellote AI, Guerendiain M, Bustamante M, Morales E, Garcia-Esteban R, Sunyer J, Franch A, Lopez-Sabater MC. Gene expression of desaturase (FADS1 and FADS2) and elongase (ELOVL5) enzymes in peripheral blood: association with polyunsaturated fatty acid levels and atopic eczema in 4-year-old children. PLoS One. 2013 Oct 22;8(10):e78245. doi: 10.1371/journal.pone.0078245

Odom DM, Talbird SE, Brogan AJ, Schenkel B. A meta-analysis of randomized, controlled trials of ustekinumab and adalimumab for moderate-to-severe psoriasis. Poster presented at the Summer Meeting of the American Academy of Dermatology; August 2013.

Eastman WJ, Malahias S, Delconte J, DiBenedetti DB. Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis. Poster presented at the Summer Academy Meeting, American Academy of Dermatology; July 2013. New York, NY.

Odom D, Brogan AJ, Talbird SE, Schenkel B. A network meta-analysis of randomized, controlled trials of ustekinumab and adalimumab for moderate-to-severe psoriasis. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2013. [abstract] Value Health. 2013 May; 16(3):A112. doi: 10.1016/j.jval.2013.03.532

Helbert M, Pang F, Alvarez-Reyes M, Pearson IV, Wolowacz S, Diwakar L. A cost-effectiveness comparison of icatibant and c1-esterase inhibitor concentrate for the symptomatic treatment of acute attacks of types i and ii hereditary angioedema in the UK setting. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 13, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A513.

Mordin M, Clark M, Doward L, Willian M. Pediatric patient-reported outcomes assessment: a case study in epidermolysis bullosa. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 9, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A480-1.

Twiss J, McKenna SP. Equating scores on two dermatology-specific patient-reported outcome measures. Poster presented at the 19th Annual Conference of the International Society for Quality of Life Research (ISOQOL); October 2012. Budapest, Hungary. [abstract] Qual Life Res. 2012 Oct; 21(1):94. doi: 10.1007/s11136-012-0248-x

Norquist JM, Girman C, Fehnel S, Demuro-Mercon C, Santanello N. Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration. Qual Life Res. 2012 Aug 1;21(6):1016-20.

Yong M, Schenfeld J, Anthony M, Pariser D, Kimball AB. Malignancy and infection rates in psoriasis patients with or without treatment and in a general population in the US: 2005 – 2009. Poster presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug; 21((Suppl 3)):42.

Salerni G, Carrera C, Lovatto L, Puig-Butille JA, Badenas C, Plana E. Benefits of total body photography and digital dermatoscopy ("two-step method of digital follow-up") in the early diagnosis of melanoma in patients at high risk for melanoma. J Am Acad Dermatol. 2012 Jul;67(1):e17-27.

Brown TM, Olanrewaju B, Deal L, Katz EC, Chiou C, Martin S, Fehnel S. Assessing pruritus among patients with atopic dermatitis: targeted literature and instrument review. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 6, 2012. [abstract] Value Health. 2012 Jun; 15(4):A253.

Yong M, Schenfeld J, Anthony MS, Kimball AB. Incidence rates of malignancies and hospitalized infectious events in psoriasis patients with or without treatment and a general population in the United States: 2005–2009. Poster presented at the American Academy of Dermatology 70th Annual Meeting; March 2012. San Diego, CA. [abstract] J Am Acad Dermatol. 2012 Apr; 66(4):AB6.

Twiss J, Meads DM, Preston EP, Crawford SR, McKenna SP. Can we rely on the Dermatology Life Quality Index (DLQI) as a measure of the impact of psoriasis or atopic dermatitis? J Invest Dermatol. 2012 Jan;132(1):76-84. doi: 10.1038/jid.2011.238

Yong M, Schenfeld J, Creamer K, Shi Y, Aras G, Anthony MS. External comparator data for the observational post-marketing safety surveillance registry of enbrel® (etanercept) for the treatment of psoriasis – a single-arm registry study. Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2011. Chicago, IL. [abstract] Pharmacoepidemiol Drug Saf. 2011 Aug; 20(S1):S228.

Primatesta P, Plana E, Aponte Z. Risk of incident cardiovascular disease events in patients with psoriasis: a retrospective cohort study using the general practice research database. Presented at the 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2011. Chicago, IL.

Arana A, Wentworth CE, Rivero E, Plana E, Conde E. Lymphoma among patients with atopic dermatitis treated with topical corticosteroids and/or topical calcineurin inhibitors. Presented at the 69th Congress of the American Academy of Dermatology; February 2011. New Orleans, LA. Previously presented at the 26th International Conference on Pharmacoepidemiology.

Arana A, Wentworth CE, Rivero E. Lymphoma among patients with atopic dermatitis treated with topical corticosteroids and/or topical calcineurin inhibitors. Poster presented at the 19th Congress of the European Academy of Dermatology and Venereology; October 6, 2010. Gothenburg, Sweden. [abstract] J Am Acad Dermatol. 2011 Feb; 64(2(1)):AB3. Previously presented at the 26th International Conference on Pharmacoepidemiology.

Arana A, Wentworth CE, Fernandez-Vidaurre C. Incidence of cancer in the context of atopic dermatitis: reply from authors. Br J Dermatol. 2011;164(4):896-7.

Twiss J, McKenna S, Crawford SR, Doward LC. Scaling properties of two commonly used outcome measures in dermatology – the Dermatology Life Quality Index (DLQI) and the Psoriasis Quality of Life Scale (PSORIQoL). Presented at the 13th Annual European Congress; November 2010. Prague, Czech Republic. [abstract] Value Health. 2010 Nov; 13(7):A244.

Mladsi D. Review of utility estimates in atopic dermatitis. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. Prague, Czech Republic. [abstract] Value Health. 2010 Nov; 13(7):A402.

Arana A, Wentworth CE, Rivero E, Plana E, Conde E. Lymphoma among patients with atopic dermatitis treated with topical corticosteroids (TCS) and/or topical calcineurin inhibitors (TCIs). Poster presented at the 26th International Conference on Pharmacoepidemiology; August 2010. Brighton, England. [abstract] Pharmacoepidemiol Drug Saf. 2010 Aug; 19(S1):S12.

Arana A, Wentworth CE, Fernández-Vidaurre C, Schlienger RG, Conde E, Arellano FM. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. Br J Dermatol. 2010;163(5):1036-43.

Twiss J, McKenna SP, Preston E, Meads DM. Can we rely on scores from the dermatology life quality index? Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A460. doi: 10.1016/S1098-3015(10)75277-3

Arbuckle R, Clark M, Harness J, Bonner N, Scott J, Draelos Z, Rizer R, Yeh Y, Copley-Merriman K. Item reduction and psychometric validation of the oily skin self assessment scale (OSSAS) and the oily skin impact scale (OSIS). Value Health. 2009 Jul 1;12(5):828-37.

Mirabelli MC, Zock JP, Bircher AJ, Jarvis D, Keidel D, Kromhout H, Norbäck D, Olivieri M, Plana E. Metalworking exposures and persistent skin symptoms in the ECRHS II and SAPALDIA 2 cohorts. Contact Dermatitis. 2009 May;60(5):256-63.

Arbuckle R, Atkinson M, Clark MJ, Abetz-Webb L, Lohs J, Kuhagen I, Harness J, Draelos Z, Thiboutot D, Blume-Paytavi U, Copley-Merriman K. Patient experiences with oily skin: the qualitative development of content for two new patient reported outcome questionnaires. Poster presented at the American Academy of Dermatology Meeting; March 1, 2009.

Harness J, Mamolo C, DeMuro-Mercon CJ, Fehnel SE, Hill C, Thompson M, Olsen EA, Price VH, Williams VS. The women's hair growth questionnaire: development and validation of a patient-reported measure for treatment efficacy in alopecia. Poster presented at the 2009 American Academy of Dermatology; March 2009.

Harness J, Draelos Z, Thiboutot D, Blume-Paytavi U, Mamolo C, Arbuckle R, Atkinson M, Clark M, Abetz L, Lohs J, Kuhagen I, Copley-Merriman K. Patient experiences with oily skin: the development of two new patient- reported outcomes questionnaires. Presented at the Annual Meeting of the American Academy of Dermatology; March 2009. San Francisco, CA.

Mamolo C, Harness J, Arbuckle R, Bonner N, Clark MJ, Scott J, Copley-Merriman K. Psychometric validation of the oily skin self-assessment and the oily skin impact scale (OSIS). Poster presented at the American Academy of Dermatology Meeting; March 1, 2009.

Davis KL, Mitra D, Kotapati S, Ibrahim R, Wolchok JD. Direct economic burden of high risk and metastatic melanoma: evidence from the SEER-Medicare linked database. Appl Health Econ Health Policy. 2009;7(1):31-41.

Arellano FM, Arana A, Wentworth CE, Fernández-Vidaurre C C, Schlienger RG, Conde E. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol Pract. 2009;123(5):111-6-116.

Arbuckle R, Atkinson MJ, Clark M, Abetz L, Lohs J, Kuhagen I, Harness J, Draelos Z, Thiboutot D, Blume-Peytavi U, Copley-Merriman K. Patient experiences with oily skin: the qualitative development of content for two new patient reported outcome questionnaires. Health Qual Life Outcomes. 2008 Oct 16;6:80. doi: 10.1186/1477-7525-6-80.

McKenna SP, Doward LC. Quality of life of children with atopic dermatitis and their families. Current Opinion Allergy Clin Immunol. 2008 Jun 1;8(3):228-31.

Clark M. Reader seeks clarification on hand-foot skin reaction. Clin J Oncol Nurs. 2008 Jun 1;12(3):395.

Mitra D, Davis KL, Kotapati S, Iloeje U. Real-world treatment patterns in high-risk and metastatic melanoma: evidence from the SEER-medicare linked database. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A83.

Mitra D, Davis KL, Kotapati S, Iloeje U. Real-world patterns of systemic therapy utilization in high risk and metastatic melanoma: evidence from the SEER-medicare linked database. Poster presented at the Annual Meeting of the American Society of Clinical Oncology; May 2008.

Kotapati S, Mitra D, Davis KL, Iloeje U. Predictors of treatment choice in high-risk and metastatic melanoma: evidence from linked electronic medical records and administrative claims data. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A82-3.

Arellano FM, Arana A, Wentworth CE. Occurrence of lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. Presented at the 24th International Conference on Pharmacoepidemiology; 2008.

Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007 Dec;143(12):1559-65.

Marton J, Jackel J, Carson R, Rothermel C, Menzin J. Predictors of costs for skin and skin structure infections due to staphylococcus aureus using a managed-care perspective. Poster presented at the 2007 ISPOR 10th Annual European Congress; October 2007. Dublin, Ireland. [abstract] Value Health. 2007 Nov; 10(6):A446.

McKenna SP, Doward LC, Meads DM, Tennant A, Lawton G, Grueger J. Quality of life in infants and children with atopic dermatitis: addressing issues of differential item functioning across countries in multinational clinical trials. Health Qual Life Outcomes. 2007;5(45).